ABBV vs DHR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
QuantHub Verdict
DHR has more upside to fair value
(+13.2%).
DHR trades at a lower forward P/E
(33.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DHR |
| Current Price |
$197.69 |
$174.04 |
| Fair Value Estimate |
$219.51 |
$197.01 |
| Upside to Fair Value |
+11.0%
|
+13.2%
|
| Market Cap |
$349.7B |
$123.2B |
| Forward P/E |
83.3x
|
33.4x
|
| EV / EBITDA |
23.4x
|
20.3x
|
| Price / Sales |
5.7x
|
5.0x
|
| Price / FCF |
18.7x
|
23.3x
|
| Revenue Growth YoY |
+10.0%
|
+3.7%
|
| Gross Margin |
70.2%
|
60.7%
|
| Operating Margin |
26.7%
|
21.0%
|
| Return on Equity |
-361.6%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
4.3%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
Accumulation Zones
| Metric |
ABBV |
DHR |
| Zone Low |
$164.63 |
$147.76 |
| Zone High |
$186.58 |
$167.46 |
| In Buy Zone? |
No
|
No
|